Furthermore, there were no positive trials among the 21 micro-cap companies (ie, companies with less than $300 million market capitalization [ http://www.investopedia.com ]), whereas 21 of 27 studies reported by the larger companies analyzed (greater than $1 billion capitalization) were positive.